SLS SELLAS Life Sciences Group, Inc.
USHealthcareAs of 2026-08-24
Why SLS matters now
SELLAS Life Sciences Group, Inc. (SLS) is a US stock in Healthcare. The latest InvestLog snapshot shows $14.33 with -7.34% on the session and $2.66B in market capitalization; recent performance reads 1-month +6.06% and YTD +113.53%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-8.4M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -2.5%.
The latest indexable market news headline is "This One Data Readout Could Make Or Break Sellas Life Sciences Group" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $2.80; recent insider activity includes Stergiou Angelos M. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
12.93
P/S
0.00
EV/EBITDA
-46.50
DCF Value
$0.63
FCF Yield
-2.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.1%
ROA
-25.8%
ROIC
-29.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.4M | $-0.05 |
| Q4 2025 | $0.00 | $-7.7M | $-0.05 |
| FY 2025 | $0.00 | $-26.9M | $-0.25 |
| Q3 2025 | $0.00 | $-6.8M | $-0.06 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$2.80
Target (Median)
$2.80
Target Range
$2.40 - $3.20
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.53
SELLAS Life Sciences Group, Inc. operates as a late-stage biopharmaceutical entity, dedicated to advancing novel cancer immunotherapies for various cancer indications across the United States. Its primary investigational product, galinpepimut-S (GPS), is a cancer immunotherapeutic agent engineered to target Wilms tumor 1. GPS is currently in Phase III clinical trials for acute myeloid leukemia and Phase 1/2 studies for ovarian cancer. Additionally, the company is progressing nelipepimut-S, an immunotherapy aimed at human epidermal growth factor receptor 2, which is undergoing Phase 2b clinical evaluation for early-stage breast cancer. A strategic collaboration with Merck & Co., Inc. is underway to assess GPS in combination with the PD1 blocker pembrolizumab, specifically within a Phase 1/2 clinical trial encompassing up to five distinct cancer indications, including both hematologic malignancies and solid tumors. Founded in 2012, SELLAS maintains its corporate headquarters in New York, New York.